{"hands_on_practices": [{"introduction": "Health technologies often involve costs and benefits that stretch over many years. To make a fair comparison, we must account for the time value of moneyâ€”the principle that a dollar today is worth more than a dollar in the future. This practice will guide you through the fundamental technique of discounting, allowing you to calculate the present value ($PV$) of a future stream of costs, a crucial first step in any robust health technology assessment. [@problem_id:4535055]", "problem": "A preventive medicine program is undergoing Health Technology Assessment (HTA) to inform the adoption of a community-based digital blood pressure monitoring platform. The technology requires an annual license and support fee of $1{,}000$ United States dollars (USD), paid at the end of each year for $5$ consecutive years, starting one year after program initiation. Following standard welfare-economic practice in HTA, future monetary flows are valued using discrete compounding with a constant real social discount rate $r = 0.03$ per year. Using first principles of present value under discrete discounting, compute the present value at program start of this $5$-year cost stream. Round your final answer to four significant figures and express the final amount in United States dollars (USD).", "solution": "The problem is subjected to validation before a solution is attempted.\n\n### Step 1: Extract Givens\n-   Annual license and support fee, $C$: $1{,}000$ United States dollars (USD).\n-   Payment schedule: Paid at the end of each year.\n-   Duration of payments, $n$: $5$ consecutive years.\n-   Timing of first payment: One year after program initiation.\n-   Discounting method: Discrete compounding.\n-   Constant real social discount rate, $r$: $0.03$ per year.\n-   Objective: Compute the present value ($PV$) at program start of the $5$-year cost stream.\n-   Rounding requirement: Round the final answer to four significant figures.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is assessed for validity.\n-   **Scientifically Grounded:** The problem is based on the standard and fundamental economic principle of the time value of money, specifically the calculation of present value using a discrete social discount rate. This is a core concept in Health Technology Assessment (HTA) and welfare economics. The values provided are realistic. The problem is scientifically sound.\n-   **Well-Posed:** The problem statement is clear, and all necessary data for the calculation are provided: the amount of each payment ($C$), the number of payments ($n$), the timing of the payments (at the end of each year, i.e., an ordinary annuity), and the discount rate ($r$). A unique and meaningful solution exists.\n-   **Objective:** The problem is stated in precise, unbiased language.\n\nThe problem does not exhibit any of the flaws listed in the validation criteria (e.g., scientific unsoundness, incompleteness, ambiguity). All conditions for a valid problem are met.\n\n### Step 3: Verdict and Action\nThe problem is **valid**. A solution will be provided.\n\n### Solution Derivation\nThe problem requires the calculation of the present value ($PV$) of a series of future costs. The specified cost stream is a uniform series of payments made at the end of each period, which is defined as an ordinary annuity. The calculation will be based on first principles of discrete discounting.\n\nLet $C$ be the constant annual cost, $r$ be the annual discount rate, and $n$ be the total number of years over which the cost is incurred. The present value of a single cost $C$ paid at the end of year $t$ is given by the formula:\n\n$$PV_t = \\frac{C}{(1+r)^{t}}$$\n\nThe total present value of the entire cost stream is the sum of the present values of each of the $n$ individual payments. The payments are made at the end of years $t=1, 2, 3, 4, 5$.\n\n$$PV = \\sum_{t=1}^{n} \\frac{C}{(1+r)^{t}}$$\n\nThe given values are:\n-   Annual cost $C = 1000$ USD.\n-   Annual discount rate $r = 0.03$.\n-   Number of payments $n = 5$.\n\nSubstituting these into the summation:\n\n$$PV = \\sum_{t=1}^{5} \\frac{1000}{(1+0.03)^{t}}$$\n\nWe can factor out the constant cost $C$:\n\n$$PV = C \\sum_{t=1}^{n} \\left(\\frac{1}{1+r}\\right)^{t}$$\n\nThe summation term is a finite geometric series with first term $a = \\frac{1}{1+r}$ and common ratio $q = \\frac{1}{1+r}$. The sum of the first $n$ terms of a geometric series is given by $S_n = a \\frac{1-q^n}{1-q}$.\n\nApplying this formula to our summation:\n$$ \\sum_{t=1}^{n} \\left(\\frac{1}{1+r}\\right)^{t} = \\left(\\frac{1}{1+r}\\right) \\frac{1 - \\left(\\frac{1}{1+r}\\right)^{n}}{1 - \\left(\\frac{1}{1+r}\\right)} $$\nSimplifying the denominator: $1 - \\frac{1}{1+r} = \\frac{1+r-1}{1+r} = \\frac{r}{1+r}$.\n\nSubstituting this back into the expression for the sum:\n$$ \\sum_{t=1}^{n} \\left(\\frac{1}{1+r}\\right)^{t} = \\left(\\frac{1}{1+r}\\right) \\frac{1 - (1+r)^{-n}}{\\frac{r}{1+r}} = \\frac{1 - (1+r)^{-n}}{r} $$\n\nThis yields the standard formula for the present value of an ordinary annuity:\n\n$$PV = C \\left[ \\frac{1 - (1+r)^{-n}}{r} \\right]$$\n\nNow, we substitute the numerical values into this formula:\n$$C = 1000$$\n$$r = 0.03$$\n$$n = 5$$\n\n$$PV = 1000 \\left[ \\frac{1 - (1 + 0.03)^{-5}}{0.03} \\right]$$\n$$PV = 1000 \\left[ \\frac{1 - (1.03)^{-5}}{0.03} \\right]$$\n\nFirst, calculate the term $(1.03)^{-5}$:\n$$(1.03)^{-5} \\approx 0.862608784$$\n\nNext, substitute this value back into the equation:\n$$PV \\approx 1000 \\left[ \\frac{1 - 0.862608784}{0.03} \\right]$$\n$$PV \\approx 1000 \\left[ \\frac{0.137391216}{0.03} \\right]$$\n$$PV \\approx 1000 \\times 4.579707186$$\n$$PV \\approx 4579.707186$$\n\nThe problem requires the final answer to be rounded to four significant figures. The calculated value is $4579.707186$. The first four significant digits are $4, 5, 7, 9$. The fifth significant digit is $7$. Since $7 \\ge 5$, we round up the fourth significant digit. Thus, $4579$ is rounded up to $4580$.\n\nThe present value of the cost stream is $4580$ USD.", "answer": "$$\\boxed{4580}$$", "id": "4535055"}, {"introduction": "When faced with several mutually exclusive treatment options, a systematic analysis is required to identify the most efficient choice. This exercise introduces the core workflow of cost-utility analysis, starting with the vital step of identifying and removing any \"dominated\" strategies that are clearly inefficient. You will then calculate the Incremental Cost-Effectiveness Ratio ($ICER$), a key metric that quantifies the additional cost for each additional unit of health gain, or Quality-Adjusted Life Year ($QALY$), when moving from one therapy to a more effective one. [@problem_id:4374965]", "problem": "A public payer is assessing three mutually exclusive interventions for a chronic condition using cost-utility analysis. All outcomes are expressed per patient over a one-year horizon from the health system payer perspective. Costs are measured in United States dollars (USD) and effects in quality-adjusted life years (QALYs), with all relevant adjustments already applied.\n\nThe alternatives are:\n- Standard care ($A$): expected cost $=\\$8{,}000$, expected QALYs $=0.75$.\n- Add-on therapy ($B$): expected cost $=\\$12{,}500$, expected QALYs $=0.80$.\n- Alternative therapy ($C$): expected cost $=\\$14{,}000$, expected QALYs $=0.79$.\n\nUsing only foundational definitions from cost-utility analysis in health technology assessment, do the following:\n1) Order the alternatives by increasing effectiveness (QALYs).\n2) Compute the incremental cost and incremental QALYs between adjacent alternatives in this effectiveness order.\n3) Identify any strictly or extendedly dominated alternatives and remove them from consideration.\n4) Among the remaining non-dominated alternatives, calculate the incremental cost-effectiveness ratio (ICER) of the more effective option relative to the next less effective option.\n\nExpress the final ICER in United States dollars per quality-adjusted life year (USD/QALY). Round your final answer to four significant figures. Provide only the numerical value as your final result.", "solution": "The problem requires a cost-utility analysis of three mutually exclusive interventions. The analysis is conducted from the health system payer perspective, with costs measured in United States dollars (USD) and effects in quality-adjusted life years (QALYs). The fundamental steps involve ordering the interventions by effectiveness, eliminating dominated alternatives, and then calculating the incremental cost-effectiveness ratio (ICER) for the remaining options.\n\nThe provided data for the three alternatives are:\n- Standard care ($A$): Cost $C_A = \\$8,000$, Effect $E_A = 0.75$ QALYs.\n- Add-on therapy ($B$): Cost $C_B = \\$12,500$, Effect $E_B = 0.80$ QALYs.\n- Alternative therapy ($C$): Cost $C_C = \\$14,000$, Effect $E_C = 0.79$ QALYs.\n\nThe process is as follows:\n\n**1. Order Alternatives by Effectiveness**\nThe first step is to order the interventions from the least effective to the most effective, based on their expected QALYs.\n- $E_A = 0.75$ QALYs\n- $E_C = 0.79$ QALYs\n- $E_B = 0.80$ QALYs\n\nThe order of increasing effectiveness is $A \\rightarrow C \\rightarrow B$. We can tabulate the alternatives in this order:\n$$\n\\begin{array}{c|c|c}\n\\text{Alternative} & \\text{Cost } (C) & \\text{Effect } (E) \\\\\n\\hline\nA & \\$8,000 & 0.75 \\\\\nC & \\$14,000 & 0.79 \\\\\nB & \\$12,500 & 0.80 \\\\\n\\end{array}\n$$\n\n**2. Identify Dominated Alternatives**\nNext, we must check for dominance. An alternative is strictly dominated if there is another alternative that is both more effective and less costly. An alternative is extendedly dominated if it has an ICER greater than that of a more effective alternative.\n\nLet's compare the costs and effects of the alternatives in their effectiveness order.\n- Compare Alternative $A$ and Alternative $C$: Alternative $C$ is more effective ($E_C > E_A$) and more costly ($C_C > C_A$). Neither dominates the other.\n- Compare Alternative $C$ and Alternative $B$: Alternative $B$ is more effective than Alternative $C$ ($E_B = 0.80 > E_C = 0.79$). At the same time, Alternative $B$ is less costly than Alternative $C$ ($C_B = \\$12,500 < C_C = \\$14,000$).\n\nSince Alternative $B$ provides a greater health benefit for a lower cost compared to Alternative $C$, Alternative $B$ strictly dominates Alternative $C$. A rational decision-maker would never choose Alternative $C$ when Alternative $B$ is available. Therefore, Alternative $C$ must be eliminated from further consideration.\n\n**3. Calculate the Incremental Cost-Effectiveness Ratio (ICER)**\nAfter removing the dominated Alternative $C$, we are left with two non-dominated alternatives: $A$ (Standard care) and $B$ (Add-on therapy).\n- Alternative $A$: $C_A = \\$8,000$, $E_A = 0.75$\n- Alternative $B$: $C_B = \\$12,500$, $E_B = 0.80$\n\nThe ICER is calculated for the more effective option ($B$) relative to the next less effective option ($A$). The formula for the ICER is the change in cost divided by the change in effect:\n$$\n\\text{ICER}_{B \\text{ vs } A} = \\frac{\\Delta C}{\\Delta E} = \\frac{C_B - C_A}{E_B - E_A}\n$$\n\nWe compute the incremental cost and incremental effect:\n- Incremental Cost ($\\Delta C$):\n$$\n\\Delta C = C_B - C_A = \\$12,500 - \\$8,000 = \\$4,500\n$$\n- Incremental Effect ($\\Delta E$):\n$$\n\\Delta E = E_B - E_A = 0.80 \\text{ QALYs} - 0.75 \\text{ QALYs} = 0.05 \\text{ QALYs}\n$$\n\nNow, we can calculate the ICER:\n$$\n\\text{ICER}_{B \\text{ vs } A} = \\frac{\\$4,500}{0.05 \\text{ QALYs}} = \\$90,000 \\text{ per QALY}\n$$\n\nThe result is an ICER of $90,000$ USD/QALY. The problem asks for the answer to be rounded to four significant figures. The number $90,000$ can be written in scientific notation to explicitly show this precision.\n$$\n90,000 = 9.000 \\times 10^4\n$$\nThis value represents the additional cost required to gain one additional quality-adjusted life year by choosing Add-on therapy ($B$) over Standard care ($A$).", "answer": "$$\\boxed{9.000 \\times 10^{4}}$$", "id": "4374965"}, {"introduction": "Calculating an Incremental Cost-Effectiveness Ratio ($ICER$) is only half the battle; we still need to decide if the trade-off is acceptable. This is where the concept of a willingness-to-pay ($\\lambda$) threshold comes in, representing the maximum value a healthcare system places on a year of perfect health. This practice will teach you to calculate the Incremental Net Monetary Benefit ($INMB$), a powerful metric that combines costs, health outcomes, and the $\\lambda$ threshold into a single dollar value to provide a clear-cut decision on cost-effectiveness. [@problem_id:4374969]", "problem": "A national payer is conducting a health technology assessment comparing a new implantable device to standard care. The incremental effectiveness of the device relative to standard care is measured in the Quality-Adjusted Life Year (QALY), defined as a time-based measure of health benefit that weights life-years by health-related quality of life on a scale from $0$ (death) to $1$ (perfect health). The payer uses a willingness-to-pay threshold, denoted by $\\lambda$, which represents the maximum amount in dollars the system is prepared to pay per one additional QALY. \n\nSuppose the incremental effectiveness is $\\Delta \\text{QALY} = 0.45$, the incremental cost is $\\Delta \\text{Cost} = 18{,}000$ dollars, and the threshold is $\\lambda = 50{,}000$ dollars per QALY. Using the core welfare economics framing that monetizes health gains by valuing $\\Delta \\text{QALY}$ at $\\lambda$ and then offsets this value by $\\Delta \\text{Cost}$ to obtain the incremental net monetary benefit, compute the incremental net monetary benefit of the device versus standard care. Express your final result in dollars as an exact value with no rounding. Then, interpret the sign and magnitude of the computed value in terms of cost-effectiveness at the stated threshold.", "solution": "The problem is valid. It is a well-posed quantitative problem grounded in the standard principles of health economics and health technology assessment (HTA). All necessary data and definitions are provided, and the values are realistic.\n\nThe central task is to compute the incremental net monetary benefit (INMB) of a new technology compared to a standard of care. The problem defines INMB as the monetized value of the incremental health gain minus the incremental cost. The health gain is measured in Quality-Adjusted Life Years (QALYs), and its monetary value is determined by the societal willingness-to-pay threshold, $\\lambda$.\n\nThe given parameters are:\n- Incremental effectiveness, $\\Delta \\text{QALY} = 0.45$. This represents the health gain in units of quality-adjusted life years.\n- Incremental cost, $\\Delta \\text{Cost} = 18{,}000$ dollars.\n- Willingness-to-pay threshold, $\\lambda = 50{,}000$ dollars per QALY.\n\nBased on the problem's explicit framing from welfare economics, the INMB is calculated using the following formula:\n$$\n\\text{INMB} = (\\lambda \\times \\Delta \\text{QALY}) - \\Delta \\text{Cost}\n$$\nThis formula represents the net societal benefit in monetary terms. The term $(\\lambda \\times \\Delta \\text{QALY})$ represents the monetary value of the health gain, and $\\Delta \\text{Cost}$ is the additional expenditure required to achieve that gain. A positive INMB indicates that the value of the health benefit exceeds the cost, suggesting the technology is cost-effective at the given threshold $\\lambda$.\n\nWe substitute the given values into the formula:\n$$\n\\text{INMB} = (\\$50{,}000 \\text{ per QALY} \\times 0.45 \\text{ QALY}) - \\$18{,}000\n$$\nFirst, calculate the monetized value of the incremental effectiveness:\n$$\n\\lambda \\times \\Delta \\text{QALY} = 50{,}000 \\times 0.45\n$$\n$$\n50{,}000 \\times \\frac{45}{100} = 500 \\times 45 = 22{,}500\n$$\nThis result, $\\$22{,}500$, is the monetary value assigned to the $0.45$ QALY gain.\n\nNext, subtract the incremental cost from this value to find the INMB:\n$$\n\\text{INMB} = \\$22{,}500 - \\$18{,}000 = \\$4{,}500\n$$\nThe incremental net monetary benefit is $\\$4{,}500$.\n\nThe second part of the problem requires an interpretation of this result.\n- **Sign**: The INMB is positive ($ +\\$4{,}500 $). A positive INMB signifies that, at the specified willingness-to-pay threshold of $\\$50{,}000$ per QALY, the economic value of the health benefits gained from the new device is greater than its additional cost. Therefore, from an economic perspective, the intervention is deemed cost-effective and represents a net gain to the system.\n\n- **Magnitude**: The magnitude of $\\$4{,}500$ quantifies this net gain per patient treated with the new device instead of standard care. It is the surplus value, expressed in monetary units, after the costs have been accounted for.\n\nAn alternative but equivalent way to evaluate cost-effectiveness is to calculate the Incremental Cost-Effectiveness Ratio (ICER) and compare it to the threshold $\\lambda$. The ICER is defined as:\n$$\n\\text{ICER} = \\frac{\\Delta \\text{Cost}}{\\Delta \\text{QALY}}\n$$\nA technology is considered cost-effective if its ICER is less than $\\lambda$. Let's verify this for the given parameters:\n$$\n\\text{ICER} = \\frac{\\$18{,}000}{0.45 \\text{ QALY}} = \\$40{,}000 \\text{ per QALY}\n$$\nComparing the ICER to the threshold:\n$$\n\\$40{,}000 \\text{ per QALY} < \\$50{,}000 \\text{ per QALY}\n$$\nSince $\\text{ICER} < \\lambda$, the intervention is cost-effective, which is consistent with the positive INMB. The algebraic relationship is direct:\n$$\n\\text{INMB} > 0 \\iff (\\lambda \\times \\Delta \\text{QALY}) - \\Delta \\text{Cost} > 0 \\iff \\lambda \\times \\Delta \\text{QALY} > \\Delta \\text{Cost} \\iff \\lambda > \\frac{\\Delta \\text{Cost}}{\\Delta \\text{QALY}} \\iff \\lambda > \\text{ICER}\n$$\nOur calculation confirms this relationship. The positive INMB of $\\$4{,}500$ indicates that the device is cost-effective at the payer's stated threshold.", "answer": "$$\n\\boxed{4500}\n$$", "id": "4374969"}]}